C1C62-M3M4 / University of North Carolina-Chapel Hill, National Institute of Allergy and Infectious Diseases - LARVOL DELTA

CM HIV-Core008: Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3m4 in Persons With HIV-1 Suppressed on ART (clinicaltrials.gov) - P1 | N=18 | Completed | Sponsor: University of North Carolina, Chapel Hill | Active, not recruiting ➔ Completed

Trial completion • Human Immunodeficiency Virus • Infectious Disease • CD4

ChAdOx1.HIVconsvX and MVA.HIVconsvX Vaccination Is Safe and Immunogenic in PWH on ART: The CM Study (CROI 2025) - "Exclusion criteria included history of clotting disorders and prior vaccination with MVA-mpox and ChAdOx1 nCoV-19 vaccines...Conclusions We present the first results following vaccination with C62-M4 and C1C62-M3M4 in PWH on ART. Vaccination was safe and immunogenic. Analysis of unblinded safety and immunogenicity data for all study participants will be presented."

Human Immunodeficiency Virus • Infectious Disease • IFNG

CM HIV-Core008: Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3m4 in Persons With HIV-1 Suppressed on ART (clinicaltrials.gov) - P1 | N=18 | Active, not recruiting | Sponsor: University of North Carolina, Chapel Hill | Recruiting ➔ Active, not recruiting

Enrollment closed • Human Immunodeficiency Virus • Infectious Disease • CD4

CM HIV-Core008: Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3m4 in Persons With HIV-1 Suppressed on ART (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: University of North Carolina, Chapel Hill | Trial completion date: Dec 2025 ➔ Feb 2025 | Trial primary completion date: Sep 2025 ➔ Sep 2024

Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CD4

CM HIV-Core008: Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3m4 in Persons With HIV-1 Suppressed on ART (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: University of North Carolina, Chapel Hill | Trial completion date: Oct 2024 ➔ Dec 2025 | Trial primary completion date: May 2024 ➔ Sep 2025

Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CD4

CM HIV-Core008: Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3m4 in Persons With HIV-1 Suppressed on ART (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: University of North Carolina, Chapel Hill | Trial primary completion date: Dec 2023 ➔ May 2024

Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CD4

CM HIV-Core008: Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3m4 in Persons With HIV-1 Suppressed on ART (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: University of North Carolina, Chapel Hill

New P1 trial • Human Immunodeficiency Virus • Infectious Disease • CD4